

An *in vitro* demonstration of the virucidal activity of *Biocence*

In April of 2009, the first outbreak of *Influenza A*, Serotype, H1N1, was isolated in Mexico. It soon spread worldwide and by June of 2009 the World Health Organization declared a state of global pandemic (Lepek, et al, 2015). The significance of this mutable variation of *Influenza A* was a result of a genomic rearrangement or recombination between human *Influenza A/H3N2*, avian *Influenza A/H1N1* and the classical swine *Influenza A/H1N1*; this “triple re-assortment” resulting in an Eurasian “avian-like” swine *Influenza A/H1N1* virus (2015, p.5).

This was a very significant event because this was first time that various strains of the **Genus**, *Influenza A*, had a genomic recombination that created a rapidly spreading mutant virus strain. At the advice of Tim Chapman, MD., a clinical consultant for ***Biocence Technology***, I had ***Biocence*** tested Aug. 28 –Sept. 4 (final report September 18, 2009) in a BSL 3 laboratory against *Influenza A/Swine/Iowa/15/30* strain of swine *Influenza A* to see if there would be virucidal effects against this new serotype or strain. The results were significant. There was a 99.97% eradication of this mutant virus strain within 30 seconds of culture (*monkey kidney cells) inoculation. And not only did ***Biocence*** eradicate the H1N1 virus within the culture cells, but it left the culture cells infected with a non-pathogenic bacteriophage (non-pathogenic virion used in the control cell-culture) unaffected. This was significant because the H1N1 serotype was listed as an impending worldwide pandemic-producing, viral agent by the W.H.O. with proposed significant global morbidity/mortality statistics. This also demonstrated that ***Biocence*** acted as a “selective” anti-viral (antimicrobial) drug (FDA listing is a “*Human OTC Drug*”).

*In the BSL 3 laboratory they used Monkey Kidney cells for the test culture because these cells represent a very close genomic or genetic similarity to human cells.

Summary

1. ***Biocence*** demonstrated a rapid virucidal activity.
 2. ***Bicence*** demonstrated a rapid virucidal effectiveness against the Gr. V, -/ssRNA, **Family**, *Orthomyxoviridae*, **Genus**, *Influenza A*, serotype, *H1N1*
 3. ***Biocence*** demonstrated a unique and singular “*Selective*” anti-viral (pathogenic vs. non-pathogenic) activity.
-

Reference

Lepek, K., Pajak, B., Rabalski, L., Urbaniak, K., Kucharczyk, K., Markowska-Daniel, I., & Szewczyk, B. (2015). Analysis of Co-infections with Influenza A/H1N1 Strain Variants among Pigs in Poland by Multi-temperature Single-Strand Conformational Polymorphism. *Biomed Research International*, 20151-9 9p. doi:10.1155/2015/535908